Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OPERA II long-term safety of PF-00547659 in Crohn's disease
2010-024638-48Phase 2Completed
- Sponsor
- Pfizer
- Start
- May 2011
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of ontamalimab in Crohn's disease, sponsored by Pfizer. Started May 2011; status: completed.
02
Drugs
ontamalimab
03
Conditions
Crohn's disease
Beyond the preview
Go deeper on 2010-024638-48.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-024638-48.